Država: Irska
Jezik: angleščina
Source: HPRA (Health Products Regulatory Authority)
IPRATROPIUM BROMIDE
Breathe Pharmaceuticals Limited
500mcg/2ml Microgram/ML
Nebuliser Solution
2008-10-17
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ipravent 500 micrograms/2 ml nebuliser solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ampoule contains ipratropium bromide at 250 micrograms/1 ml i.e. 500 micrograms in 2 ml. For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Nebuliser Solution. A clear, colourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ipratropium bromide is indicated for the treatment of reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD). Ipratropium bromide is indicated, when used concomitantly with inhaled beta 2 -agonists, for treatment of reversible airways obstruction as in acute and chronic asthma. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The dosage should be adapted to the individual needs of the patient. In children aged 12 years and under, only Ipravent Nebuliser Solution 1 ml should be used. The following doses are recommended: _ADULTS (INCLUDING THE ELDERLY) AND CHILDREN OVER 12 YEARS OF AGE:_ 250 - 500 micrograms (i.e. one vial of 250 micrograms in 1 ml or one vial of 500 micrograms in 2ml) 3 to 4 times daily. The exact starting dose may vary depending on local guidelines. For treatment of acute bronchospasm, 500 micrograms. Repeated doses can be administered until the patient is stable. The time interval between the doses may be determined by the physician. It is advisable not to exceed the recommended daily dose during either acute or maintenance treatment. Daily doses exceeding 2 mg in adults and children over 12 years of age should only be given under medical supervision. _CHILDREN 6 - 12 YEARS OF AGE:_ 250 micrograms (i.e. one vial of 250 micrograms in 1ml) up to a total daily dose of 1mg (4 vials). The time interval between dose Preberite celoten dokument